Many people with prostate cancer can safely receive shorter, higher-dose radiation therapy after surgery, a new study has found. The approach, called HYPORT, resulted in the same quality of life as the standard course of radiation.
The CAR T-cell therapy brexucabtagene autoleucel (Tecartus) has become the first such treatment approved by the Food and Drug Administration to treat adults with acute lymphoblastic leukemia. The approval is for people whose cancer has not responded to treatment or has returned after treatment.
NCI researchers have found that adding the targeted therapy ibrutinib (Imbruvica) to standard chemotherapy can improve how long some younger people with a specific form of diffuse large B-cell lymphoma live. The findings come from a new analysis of a completed phase 3 clinical trial called Phoenix.
Informed consent is a process through which people interested in joining a clinical trial learn details about the trial before deciding whether to take part. Learn more about this critical part of ensuring patient safety in research.
Children are not able to give true informed consent until they turn 18. So, before taking part in a clinical trial, they are asked for their assent, meaning they agree to take part. Learn more about children’s assent to participate in clinical trials.
This phase 3 trial compares how often a follow-up colonoscopy should be done in people who had one or two polyps (noncancerous small growths) removed from their colon. The usual approach is to have a repeat colonoscopy in 5 to 10 years. People in this study will be randomly assigned to either the usual approach or a repeat colonoscopy at 10 years.
This clinical trial will examine how diet and exercise affect the gut microbiome in people with melanoma receiving immunotherapy. People in the trial will be assigned to either a plant-based, high-fiber diet and an exercise regimen or they will receive information about diet and exercise. Doctors want to learn more about how diet and exercise change the gut microbiome in people with melanoma.
This phase 1/2 trial will test abemaciclib (Verzenio), a drug approved for breast cancer, in people with Kaposi sarcoma. People participating in the trial may have HIV-associated or HIV-negative cancer. Researchers will evaluate the safety of the drug and decide on the best dose. They also want to see if abemaciclib causes Kaposi sarcoma tumors to shrink or go away.
